

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 July 2017 (20.07.2017)



(10) International Publication Number
WO 2017/122116 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) **A61P 3/04** (2006.01)
A61K 31/55 (2006.01)

(21) International Application Number:
PCT/IB2017/050094

(22) International Filing Date:
9 January 2017 (09.01.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/279,037 15 January 2016 (15.01.2016) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **CHAPPIE, Thomas Allen**; 59 Hemlock Hill
Road, Carlisle, Massachusetts 01741 (US). **HENDER-
SON, Jaclyn Louise**; 36 Highland Avenue, Apt. 54, Cam-
bridge, Massachusetts 02139 (US). **YOUNG, Joseph Mi-
chael**; 20156 Stanton Avenue, #36, Castro Valley, Califor-
nia 94546 (US). **WAGER, Travis T.**; 465 Washington
Street, Apt., 6, Brookline, Massachusetts 02446 (US).
KORMOS, Bethany Lyn; 46 Quincy Street, #3,
Somerville, Massachusetts 02143 (US). **PATEL, Nandini
Chaturbhai**; 34 Mary Ellen Road, Waban, Massachusetts
02468 (US). **SCIABOLA, Simone**; 109 River Street, Cam-
bridge, Massachusetts 02139 (US). **TUTTLE, Jamison
Bryce**; 24 Amherst Road, Marblehead, Massachusetts
01945 (US). **VERHOEST, Patrick Robert**; 23 Calvin
Road, Newton, Massachusetts 02460 (US). **TUCKER,
Joseph Walter**; 25 Dart Street, New London, Connecticut
06320 (US).

(74) Agent: **WALDRON, Roy F.**; Pfizer Inc., 235 East 42nd
Street, MS 235/9/S20, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS



(57) Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R^1 , R^2 , R^3 , R^4 , R^5 , a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.